All In Biotech

Drug Trial Radar · NCT05815485

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

May 4, 2023

Primary completion

Apr 2026

Study completion Apr 2026

Sponsor

Lead sponsor
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A new drug called azeliragon could be used to treat patients with COVID-19 or other pneumonia infections but the researchers don't know. In this study, they are learning the effects of azeliragon patients hospitalized for COVID-19 or pneumonia.

Conditions

  • COVID-19

Interventions

  • AzeliragonDrug

    30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).

  • PlaceboDrug

    Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs) (Phase 2 only)Time frame: Up to 28 days post-treatment
  2. Death, need for mechanical ventilation or Acute Kidney Injury (AKI) of stage 2 or higher per Kidney Disease Improving Global Outcomes (KDIGO) scale (Phase 3 only)Time frame: Day 14 of hospitalization

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Rush University

    Chicago, Illinois

  • University of Michigan

    Ann Arbor, Michigan

  • University of Texas Medical Branch

    Galveston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.